ACRV Home Investment Highlights Valuation & Metrics Price Chart Why The Stock Moved Return vs. Risk About ACRV Interactive Breakdown Better Bets vs. ACRV Peer Outperformance Latest Trefis Analyses Trade Ideas More From Trefis Peer Comparisons FDIC Bank Data FDA Approved Drugs Data Clinical Pipeline Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Forward Guidance Insider Activity Investor Activity (13F) Trade Sentinel Investor Videos Industry Resource Links External Quote Links

    Acrivon Therapeutics (ACRV)

    Market Price (10/15/2026): $1.72 | Market Cap: $72.0 MilSector: Health Care | Industry: Biotechnology

    Acrivon Therapeutics (ACRV)

    Market Price (10/15/2026): $1.72
    Market Cap: $72.0 Mil
    Sector: Health Care
    Industry: Biotechnology

    Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

    0

    Cash is significant % of market cap
    Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -122%

    Megatrend and thematic drivers
    Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Personalized Diagnostics, Show more.

    Weak multi-year price returns
    2Y Excs Rtn is -110%, 3Y Excs Rtn is -155%

    Very low revenue
    Rev LTMTotal Revenue or Sales, Last Twelve Months is 0

    Not profitable at operating income level
    Op Inc LTMOperating Income, Last Twelve Months is -78 Mil

    Yield minus risk free rate is negative
    ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -108%

    Key risks
    ACRV key risks include [1] its critical dependence on the clinical trial success and regulatory approval of its lead candidates, Show more.

    0 Cash is significant % of market cap
    Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -122%
    1 Megatrend and thematic drivers
    Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Personalized Diagnostics, Show more.
    2 Weak multi-year price returns
    2Y Excs Rtn is -110%, 3Y Excs Rtn is -155%
    3 Very low revenue
    Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
    4 Not profitable at operating income level
    Op Inc LTMOperating Income, Last Twelve Months is -78 Mil
    5 Yield minus risk free rate is negative
    ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -108%
    6 Key risks
    ACRV key risks include [1] its critical dependence on the clinical trial success and regulatory approval of its lead candidates, Show more.

    ACRV in ETFs

    Weight = ACRV's share of each fund

    VTI0.00%

    Valuation & Metrics

    FYE: 12/31ACRV [1]S&P 500 [2]
    REVENUE GROWTH
    LTM Revenue [3]$0.0 Mil—
    FY 2026 Sales$1.5 Mil—
    FY 2027 Sales$0.2 Mil—
    FY 2026 Sales Growth——
    FY 2027 Sales Growth-88.9%13.3%
    EARNINGS
    LTM Net Income (GAAP) [3]$-74.2 Mil—
    FY 2026 Net Income (Non-GAAP)$-74.9 Mil—
    FY 2027 Net Income (Non-GAAP)$-90.3 Mil—
    FY 2027 Net Income Growth—19.0%
    FY 2026 EPS (Non-GAAP)$-1.85—
    FY 2027 EPS (Non-GAAP)$-1.66—
    FY 2027 EPS Growth——
    VALUATION
    FY 2026 P/S48.01.7
    FY 2027 P/S432.8—
    FY 2026 P/E—7.7
    FY 2027 P/E——

    [1] ACRV forward figures are analyst consensus for the next two fiscal years (fiscal year end 12/31). Net Income and EPS are non-GAAP (adjusted) consensus. P/S and P/E divide the current market cap by the consensus figure.
    [2] S&P 500 figures are the SPY ETF's holdings-weighted forward aggregate. P/S and P/E reflect FY1/FY2 consensus blended to the 12-month window ending 10/31/27 (~one year forward), shown when ≥90% of index weight has estimates. Growth is the aggregate next-fiscal-year vs current-fiscal-year (FY1→FY2) change. Index-level dollar Sales, Net Income and EPS are not applicable.
    [3] LTM = reported trailing-twelve-month actuals (GAAP).
    null

    AI Analysis | Feedback

    MetricValueDateSource
    Clinical Programs in Development28132025Link
    Preclinical Programs in Development18132025Link
    Lead Program PhasePhase 2b8132025Link
    Second Clinical Candidate PhasePhase 18132025Link
    Overall Response Rate for ACR-368 in Gynecological Cancers (specific trial)50%8132024Link
    Confirmed Partial Response in Endometrial Cancer (ACR-2316 Phase 1)Observed8132025Link
    Estimated Enrollment in Phase 2 Study of ACR-3683539232025Link
    Employees7812312024Link

    Price Chart

    null
    Upcoming
    11/12/2026Earnings ReleaseRev: $0.0 Mil (E)
    EPS: $-0.45 (E)

    Why The Stock Moved

    Qualitative Assessment

    AI Analysis | Feedback

    Updated on 10/13/2026

    Acrivon Therapeutics (ACRV) stock has lost about 5% since 6/30/2026 because of the following key factors:

    1. Q2 2026 Earnings Beat and Extended Cash Runway Provided Stability, Not Major Upside.

    Acrivon Therapeutics reported Q2 2026 earnings per share (EPS) of -$0.43 on August 12, 2026, exceeding analyst consensus estimates of -$0.50. This positive earnings surprise, along with a reported cash, cash equivalents, and marketable securities balance of $90.0 million as of June 30, 2026, projected to fund operations into fiscal Q4 2027, offered financial stability. However, the stock's reaction was a modest 6.94% increase in the 48 hours following the announcement, indicating that while reassuring, these factors did not provide a significant catalyst for sustained upward movement.

    2. Steady Clinical Pipeline Advancement Without Immediate Transformative Data.

    During the period, Acrivon announced the advancement of ACR-2316, a WEE1/PKMYT1 inhibitor, into randomized dose expansion in its Phase 1/2 study on August 5, 2026, supported by a favorable safety profile and durable single-agent clinical activity. Additionally, the prespecified interim analysis for its lead program, ACR-368, in Phase 2b endometrial cancer, remained on track for the second half of 2026, with full enrollment in registrational-intent arms expected by fiscal Q4 2026. While these represent consistent progress for a clinical-stage biotechnology company, the absence of definitive, late-stage clinical trial readouts or regulatory approvals within this timeframe likely limited significant stock appreciation.

    Show more
    Updated on 10/13/2026

    Acrivon Therapeutics (ACRV) stock has lost about 5% since 6/30/2026 because of the following key factors:

    1. Q2 2026 Earnings Beat and Extended Cash Runway Provided Stability, Not Major Upside.

    Acrivon Therapeutics reported Q2 2026 earnings per share (EPS) of -$0.43 on August 12, 2026, exceeding analyst consensus estimates of -$0.50. This positive earnings surprise, along with a reported cash, cash equivalents, and marketable securities balance of $90.0 million as of June 30, 2026, projected to fund operations into fiscal Q4 2027, offered financial stability. However, the stock's reaction was a modest 6.94% increase in the 48 hours following the announcement, indicating that while reassuring, these factors did not provide a significant catalyst for sustained upward movement.

    2. Steady Clinical Pipeline Advancement Without Immediate Transformative Data.

    During the period, Acrivon announced the advancement of ACR-2316, a WEE1/PKMYT1 inhibitor, into randomized dose expansion in its Phase 1/2 study on August 5, 2026, supported by a favorable safety profile and durable single-agent clinical activity. Additionally, the prespecified interim analysis for its lead program, ACR-368, in Phase 2b endometrial cancer, remained on track for the second half of 2026, with full enrollment in registrational-intent arms expected by fiscal Q4 2026. While these represent consistent progress for a clinical-stage biotechnology company, the absence of definitive, late-stage clinical trial readouts or regulatory approvals within this timeframe likely limited significant stock appreciation.

    3. Mixed Broader Biotech Sector Performance.

    The general biotechnology sector experienced a mixed and somewhat subdued performance during fiscal Q3 2026. While the broader Health Care Select Sector SPDR® Fund ETF (XLV) gained 5.57% during Q3 2026, outpacing the S&P 500's 2.25% advance, other biotech-specific indices, such as the XBI, underperformed the broader market during this quarter. Reports indicated that biotech sector momentum stalled in fiscal Q3 2026, particularly in September, due to technical factors rather than fundamental disappointments. This broader market sentiment likely acted as a headwind, preventing Acrivon's stock from experiencing a significant breakout despite company-specific positive developments.

    Show less
    Holding a concentrated position? Know your true downside before the momentum shifts.
    Protect Your Wealth →

    Stock Movement Drivers

    Fundamental Drivers

    The -3.4% change in ACRV stock from 6/30/2026 to 10/14/2026 was primarily driven by a -7.4% change in the company's Shares Outstanding (Mil).
    (LTM values as of)630202610142026Change
    Stock Price ($)1.781.72-3.4%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)3942-7.4%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    6/30/2026 to 10/14/2026
    ReturnCorrelation
    ACRV-3.4% 
    Market (SPY)3.1%25.7%
    Sector (XLV)9.6%12.5%

    Fundamental Drivers

    The 23.7% change in ACRV stock from 3/31/2026 to 10/14/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).
    (LTM values as of)331202610142026Change
    Stock Price ($)1.391.7223.7%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)3942-7.6%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    3/31/2026 to 10/14/2026
    ReturnCorrelation
    ACRV23.7% 
    Market (SPY)18.6%34.8%
    Sector (XLV)19.2%14.2%

    Fundamental Drivers

    The -5.0% change in ACRV stock from 9/30/2025 to 10/14/2026 was primarily driven by a -8.1% change in the company's Shares Outstanding (Mil).
    (LTM values as of)930202510142026Change
    Stock Price ($)1.811.72-5.0%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)3842-8.1%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    9/30/2025 to 10/14/2026
    ReturnCorrelation
    ACRV-5.0% 
    Market (SPY)16.5%28.3%
    Sector (XLV)26.6%19.0%

    Fundamental Drivers

    The -82.0% change in ACRV stock from 9/30/2023 to 10/14/2026 was primarily driven by a -47.5% change in the company's Shares Outstanding (Mil).
    (LTM values as of)930202310142026Change
    Stock Price ($)9.561.72-82.0%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)2242-47.5%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    9/30/2023 to 10/14/2026
    ReturnCorrelation
    ACRV-82.0% 
    Market (SPY)86.2%25.0%
    Sector (XLV)41.5%20.4%

    Return vs. Risk

    Price Returns Compared

     202120222023202420252026Total [1]
    Returns
    ACRV Return--31%-57%22%-60%-27%-89%
    Peers Return6%-56%27%-44%19%47%-42%
    S&P 500 Return27%-19%24%23%16%14%108%

    Monthly Win Rates [3]
    ACRV Win Rate-0%33%50%67%30% 
    Peers Win Rate50%33%50%37%43%48% 
    S&P 500 Win Rate75%42%67%75%67%50% 

    Max Drawdowns [4]
    ACRV Max Drawdown---84%-49%-85%-57% 
    Peers Max Drawdown-48%-78%-60%-68%-65%-43% 
    S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 

    [1] Cumulative total returns since the beginning of 2021
    [2] Peers: ZNTL, APRE, IDYA, TNGX, ORIC.
    [3] Win Rate = % of calendar months in which monthly returns were positive
    [4] Max drawdown represents maximum peak-to-trough decline within a year
    [5] 2026 data is for the year up to 10/14/2026 (YTD)

    About Acrivon Therapeutics (ACRV)

    Acrivon Therapeutics (ACRV) is a clinical-stage biopharmaceutical company dedicated to developing precision oncology medicines. The company distinguishes itself by moving beyond traditional genomics-based patient selection methods, which often target a small percentage of cancer patients. Instead, Acrivon employs its proprietary proteomics-based platform, Acrivon Predictive Precision Proteomics (AP3), to create drug-specific OncoSignature companion diagnostics. This innovative platform directly measures critical tumor-driving proteins to identify patients whose tumors are predicted to be most sensitive to a specific medicine, thereby expanding the potential treatable population across a broader range of cancers.

    The company's lead product candidate is ACR-368 (also known as prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2. ACR-368 is currently advancing in a potentially registrational Phase 2 trial under an FDA master protocol, initially focusing on patients with platinum-resistant ovarian, endometrial, or bladder cancer. Patients in this trial are stratified for treatment based on their OncoSignature-predicted sensitivity to ACR-368. Acrivon also plans to study ACR-368 in additional indications such as HPV+ squamous cell carcinomas, building on demonstrated clinical activity and OncoSignature-based predictions of sensitivity.

    In addition to ACR-368, Acrivon is developing a preclinical pipeline of internally discovered programs targeting key nodes in DNA Damage Response and cell cycle regulation pathways, including WEE1 and PKMYT1. By leveraging its AP3 platform, Acrivon aims to significantly accelerate drug development, increase the probability of successful treatment outcomes, and ultimately address a much larger percentage of solid tumors for which genetics-based approaches have been insufficient to identify patient responders.

    AI Analysis | Feedback

    Here are 1-3 brief analogies for Acrivon Therapeutics:
    • Acrivon Therapeutics is like 23andMe for cancer treatment, but instead of using DNA to understand inherited risks, they use protein analysis to precisely match patients with the right drugs for their tumor.
    • Acrivon is like Waze for cancer drug development, using real-time molecular insights (proteins) to find the most efficient path for a drug to reach the right patients, rather than relying on older, static maps (genetics).

    AI Analysis | Feedback

    • ACR-368 (Prexasertib): A clinical-stage small molecule inhibitor targeting CHK1 and CHK2, currently in a potentially registrational Phase 2 trial for various solid tumors.
    • Acrivon Predictive Precision Proteomics (AP3) Platform: A proprietary proteomics-based platform used to identify patient responders for oncology drug candidates and create drug-specific OncoSignature companion diagnostics.

    AI Analysis | Feedback

    As a clinical-stage biopharmaceutical company, Acrivon Therapeutics (ACRV) is currently focused on the development of precision oncology medicines and companion diagnostics, advancing its lead candidate, ACR-368, through Phase 2 clinical trials. At this stage of development, the company does not have commercial products on the market.

    Therefore, Acrivon Therapeutics does not currently have major customers that purchase its products or services.

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    The key risks to Acrivon Therapeutics' business are:

    1. Clinical Trial Success and Regulatory Approval of Lead Drug Candidate (ACR-368): Acrivon is a clinical-stage biopharmaceutical company, and the success of its lead candidate, ACR-368, in its ongoing "potentially registrational Phase 2 trial" is paramount. There is inherent risk in drug development, and failure to achieve favorable results in clinical trials or to obtain regulatory approval from bodies like the FDA would significantly impact the company's ability to commercialize its primary asset.
    2. Regulatory Approval and Efficacy of the AP3 Platform and OncoSignature Companion Diagnostics: Acrivon's core strategy relies on its proprietary proteomics-based patient responder identification platform (AP3) and its drug-specific OncoSignature companion diagnostics. The company explicitly states that its "ACR-368 OncoSignature test... has not yet obtained regulatory approval." The successful development, validation, and regulatory approval of this companion diagnostic are critical to its precision medicine approach and its ability to identify patient responders, which it believes will increase overall response rates and accelerate clinical development. Failure to secure regulatory approval for this platform or if it does not perform as anticipated in identifying sensitive patients, would undermine its entire business model and pipeline.

    AI Analysis | Feedback

    The primary clear emerging threat for Acrivon Therapeutics is the regulatory approval and prospective clinical validation of its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), and its associated OncoSignature companion diagnostic. The company explicitly states that the "ACR-368 OncoSignature test, which has not yet obtained regulatory approval." The success of their lead candidate, ACR-368, in its potentially registrational Phase 2 trial is contingent upon this OncoSignature test successfully identifying patient responders and receiving regulatory approval. A failure to secure regulatory approval for the diagnostic, or if the AP3 platform and OncoSignature test fail to demonstrate robust prospective predictive power and patient enrichment in the ongoing registrational-intent clinical trials, would undermine Acrivon Therapeutics' core precision oncology strategy and its ability to bring its drug candidates to market as intended.

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    Here are 3-5 expected drivers of future revenue growth for Acrivon Therapeutics (ACRV) over the next 2-3 years:

    1. Advancement and potential regulatory approval of ACR-368 (prexasertib) for initial indications: Acrivon is currently advancing its lead candidate, ACR-368, in a potentially registrational Phase 2 trial for patients with platinum-resistant ovarian, endometrial, or bladder cancer. Successful completion of this trial and subsequent regulatory approval would be a primary driver of revenue growth as the company could begin commercializing the drug in these high-unmet-need indications.
    2. Expansion of ACR-368 into additional tumor types: Beyond its initial registrational trial, Acrivon plans to study ACR-368 in additional indications, such as human papilloma virus positive (HPV+) squamous cell carcinomas, including head and neck (SCCHN), anal, and cervical cancer. Successful clinical development and eventual approval in these expanded markets would significantly broaden the patient population and potential revenue streams for ACR-368.
    3. Commercialization and adoption of the proprietary OncoSignature companion diagnostic: Integral to Acrivon's strategy is its proprietary proteomics-based patient responder identification platform, AP3, which enables the creation of drug-specific OncoSignature companion diagnostics. The successful development, regulatory approval, and widespread adoption of the ACR-368 OncoSignature test are crucial for identifying patient responders and maximizing the efficacy and market potential of ACR-368, indirectly driving drug revenue and potentially generating revenue from the diagnostic itself.
    4. Strategic partnerships and collaborations: As Acrivon progresses its lead candidate ACR-368 and its innovative AP3 platform, the company may pursue strategic partnerships or collaborations. These could involve licensing agreements for specific regions, co-development deals, or partnerships to apply the AP3 platform to other drug candidates, generating revenue through upfront payments, milestone achievements, and royalties.

    AI Analysis | Feedback

    Share Issuance

    • Acrivon Therapeutics priced its initial public offering on November 14, 2022, offering 7,550,000 shares of common stock at a price of $12.50 per share.
    • Concurrently with the IPO in November 2022, the company sold an additional 400,000 shares of common stock to an existing stockholder, Chione Limited, through a private placement. The gross proceeds from the IPO and this concurrent private placement were approximately $99.4 million.
    • In April 2024, Acrivon completed a private investment in public equity (PIPE) financing, issuing 8,235,000 shares of common stock at $8.50 per share and pre-funded warrants for up to 7,060,000 shares at $8.499 per warrant, raising approximately $130 million in gross proceeds.

    Inbound Investments

    • Prior to its IPO in November 2022, Acrivon Therapeutics secured $100 million in an oversubscribed Series B financing round in November 2021.
    • The company completed a private investment in public equity (PIPE) financing in April 2024, with new and existing accredited investors providing approximately $130 million in gross proceeds.

    Capital Expenditures

    • Acrivon Therapeutics invested $899K in capital expenditures in Q3 2025, primarily funding long-term assets and infrastructure.
    • Capital expenditures for the 12 months prior to Q3 2025 amounted to $2.28 million.
    • The company anticipates that its cash, cash equivalents, and investments are sufficient to fund operating expenses and capital expenditure requirements into the second quarter of 2027.

    Peer Outperformance in Biotechnology

    null
    Share of Biotechnology constituents that ACRV has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
    1Y
    64%
    of 450 industry peers · -1.1% return
    3Y
    32%
    of 396 industry peers · -71.1% return
    5Y
    —
    insufficient peer history
    null
    Median price return by industry across the Health Care sector, ranked by 5Y. Biotechnology is ACRV's own industry. Use this to see which corners of the sector have carried the returns.
    Industry Names 1Y med3Y med5Y med Top 3 by 5Y
    Health Care Distributors 6 15.2%47.5%101.1% CAH 456% · MCK 395% · COR 193%
    Health Care Services 20 21.8%36.8%9.2% HIMS 256% · RDNT 152% · DGX 80%
    Managed Health Care 8 40.1%-2.3%8.0% OSCR 133% · HQY 42% · ELV 22%
    Health Care Facilities 24 3.2%18.1%6.2% THC 337% · NHC 272% · EHC 144%
    Health Care Equipment 50 -2.1%3.7%-13.7% UFPT 365% · GKOS 252% · TMDX 183%
    Pharmaceuticals 61 -8.9%-4.7%-32.7% LQDA 720% · KNSA 573% · CORT 459%
    Health Care Supplies 12 29.1%-4.7%-35.3% LNTH 328% · HAE 74% · MMSI 22%
    Life Sciences Tools & Services 109 -13.5%-6.4%-67.0% NTRA 257% · MEDP 232% · GH 59%
    Biotechnology ← 361 -24.8%-28.4%-81.2% DNTH 1023% · ELVN 926% · ADMA 804%
    Health Care Technology 22 -27.8%-63.0%-83.6% VEEV 1% · DOCS -61%
    Median of constituents with a full price history over each window. Top names are limited to companies above $2B market cap.

    Latest Trefis Analyses

    TitleDate
    0DASHBOARDS 
    1Acrivon Therapeutics Earnings Notes12/16/2025
    Title
    0ARTICLES

    Recent Active Movers

    Top Gainers

    TickerCompanyMkt Cap (B)1W RtnYTD Rtn
    PCRXPacira BioSciences1.444.4%40.6%
    FIGSFIGS3.132.5%64.0%
    LQDALiquidia3.027.2%-1.6%
    HAEHaemonetics5.519.1%51.1%
    CCCCCC Intelligent Solutions4.416.6%-3.9%
    HPKHighPeak Energy1.216.3%109.1%
    ETSYEtsy7.816.0%49.6%
    COCOVita Coco3.415.6%10.5%
    MRNAModerna90.115.2%667.4%
    CCICrown Castle34.415.0%-7.2%

    Top Losers

    TickerCompanyMkt Cap (B)1W RtnYTD Rtn
    NUAINew Era Energy & Digital0.3-38.3%16.4%
    EOSEEos Energy Enterprises0.7-37.1%-83.0%
    CTNMContineum Therapeutics0.3-36.1%-28.8%
    CIFRCipher Digital4.1-31.7%-32.7%
    SHAZSharonAI0.6-31.3%-66.5%
    ASTSAST SpaceMobile12.6-30.5%-42.0%
    BRUNBoost Run0.6-29.8%-54.0%
    AAOIApplied Optoelectronics7.0-29.6%147.3%
    BLZEBackblaze0.6-29.2%108.7%
    XNDUXanadu Quantum Technologies1.0-29.0%-72.3%

    Top Gainers

    TickerCompanyMkt Cap (B)1M RtnYTD Rtn
    MYPSPLAYSTUDIOS0.5723.2%521.2%
    KODKodiak Sciences5.1145.8%190.0%
    GRALGRAIL6.084.1%63.2%
    DNAGinkgo Bioworks0.764.9%38.7%
    MRNAModerna90.157.4%667.4%
    IOVAIovance Biotherapeutics6.451.8%420.5%
    PCRXPacira BioSciences1.451.2%40.6%
    PACBPacific Biosciences of California0.648.5%6.4%
    SGSweetgreen1.248.5%50.0%
    RXORXO4.946.6%127.0%

    Top Losers

    TickerCompanyMkt Cap (B)1M RtnYTD Rtn
    CTVACorteva9.0-83.9%-79.9%
    XNDUXanadu Quantum Technologies1.0-59.1%-72.3%
    EMATEvolution Metals & Technologies0.9-54.7%-93.0%
    GLASGlass House Brands0.3-54.1%-58.3%
    EOSEEos Energy Enterprises0.7-52.1%-83.0%
    QUREuniQure1.4-51.3%-12.4%
    LQDALiquidia3.0-48.4%-1.6%
    NKTRNektar Therapeutics1.2-44.6%-12.7%
    UNITUniti1.4-42.3%-19.5%
    PCTPureCycle Technologies0.6-42.3%-62.5%

    More From Trefis

    Research & Analysis

    Invest in Strategies

    Wealth Management

    Peer Comparisons

    Peers to compare with:

    Financials

    ACRVZNTLAPREIDYATNGXORICMedian
    NameAcrivon .Zentalis.Aprea Th.IDEAYA B.Tango Th.ORIC Pha. 
    Mkt Price1.722.240.5933.5122.5111.616.92
    Mkt Cap0.10.20.03.13.41.30.7
    Rev LTM0002345400
    Op Inc LTM-78-153-13-217-136-156-145
    FCF LTM-64-128-12-114-144-112-113
    FCF 3Y Avg-64-149-13-182-138-111-125
    CFO LTM-63-128-12-112-144-112-112
    CFO 3Y Avg-62-149-13-179-137-111-124

    Growth & Margins

    ACRVZNTLAPREIDYATNGXORICMedian
    NameAcrivon .Zentalis.Aprea Th.IDEAYA B.Tango Th.ORIC Pha. 
    Rev Chg LTM--100.0%-3,244.7%121.5%-121.5%
    Rev Chg 3Y Avg---1,043.2%34.9%-539.1%
    Rev Chg Q-----100.0%--100.0%
    QoQ Delta Rev Chg LTM---3.9%-5.6%--0.8%
    Op Inc Chg LTM17.0%10.5%10.6%43.5%13.3%-4.3%12.0%
    Op Inc Chg 3Y Avg-20.4%12.2%4.2%-61.0%-7.2%-19.3%-13.2%
    Op Mgn LTM----92.7%-253.4%--173.0%
    Op Mgn 3Y Avg----2,393.9%-404.1%--1,399.0%
    QoQ Delta Op Mgn LTM----11.2%-47.2%--29.2%
    CFO/Rev LTM----47.7%-267.4%--157.6%
    CFO/Rev 3Y Avg----1,778.5%-386.7%--1,082.6%
    FCF/Rev LTM----48.6%-268.1%--158.4%
    FCF/Rev 3Y Avg----1,806.2%-388.8%--1,097.5%

    Valuation

    ACRVZNTLAPREIDYATNGXORICMedian
    NameAcrivon .Zentalis.Aprea Th.IDEAYA B.Tango Th.ORIC Pha. 
    Mkt Cap0.10.20.03.13.41.30.7
    P/S---13.262.7-37.9
    P/Op Inc-0.9-1.0-2.4-14.2-24.7-8.0-5.2
    P/EBIT-0.9-1.0-2.4-14.2-24.7-8.0-5.2
    P/E-1.0-1.1-2.5-17.6-27.3-8.9-5.7
    P/CFO-1.1-1.2-2.6-27.6-23.4-11.2-6.9
    Total Yield-103.1%-84.3%-39.7%-5.6%-3.7%-11.2%-25.4%
    Dividend Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%
    FCF Yield 3Y Avg-67.3%-91.8%-85.2%-8.1%-14.1%-15.0%-41.1%
    D/E0.00.20.00.00.00.00.0
    Net D/E-1.2-0.9-1.3-0.3-0.3-0.2-0.6

    Returns

    ACRVZNTLAPREIDYATNGXORICMedian
    NameAcrivon .Zentalis.Aprea Th.IDEAYA B.Tango Th.ORIC Pha. 
    1M Rtn-12.2%-36.0%-24.7%-11.9%-8.3%-8.3%-12.1%
    3M Rtn-10.4%-53.1%-15.7%-8.8%-25.6%4.2%-13.1%
    6M Rtn3.0%-58.2%-37.6%4.1%-11.1%12.9%-4.1%
    12M Rtn-1.1%45.5%-61.1%23.8%158.7%-11.8%11.3%
    3Y Rtn-71.6%-88.2%-88.8%34.1%192.7%108.5%-18.8%
    1M Excs Rtn-8.9%-31.3%-24.4%-13.9%-8.7%-9.0%-11.5%
    3M Excs Rtn-5.3%-54.5%-18.4%-10.3%-22.2%4.5%-14.4%
    6M Excs Rtn-8.2%-69.0%-48.9%-6.9%-22.5%1.7%-15.3%
    12M Excs Rtn-20.1%21.5%-77.5%8.0%148.2%-33.9%-6.1%
    3Y Excs Rtn-154.9%-165.8%-169.3%-54.0%46.8%7.9%-104.4%

    Comparison Analyses

    null

    Financials

    $ Mil | FY: 12/312026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q3
    Period End6/30/20263/31/202612/31/20259/30/20256/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/2023
    Filing Date8/12/20265/13/20263/19/202611/13/20258/13/20255/14/20253/27/202511/13/20248/13/20245/14/20243/28/202411/9/2023
    Key Financials Quarterly            
    Total Revenue000000000000
    Ebitda-18-20-20-19-22-21-25-25-21-17-21-16
    Operating Income-19-20-20-20-23-22-25-25-21-18-21-16
    Net Income-18-19-19-18-21-20-23-22-19-16-19-14
    EPS-0.43-0.49-0.49-0.47-0.55-0.51-0.60-0.59-0.52-0.73-0.87-0.66
    Key Financials TTM            
    Total Revenue TTM000000000000
    Ebitda TTM-77-81-83-88-93-92-88-84-76-70-67-55
    Operating Income TTM-78-82-84-89-94-93-89-85-76-70-67-56
    Net Income TTM-74-77-78-82-86-84-81-77-69-64-60-50
    Growth Rates Quarterly            
    Total Revenue Growth------------
    EBITDA Growth18.2%8.6%19.9%22.3%-5.2%-22.4%-17.9%-55.5%-37.8%-22.3%-112.9%-69.2%
    Operating Income Growth17.6%8.1%19.4%21.7%-5.7%-22.6%-18.5%-55.8%-38.1%-22.8%-111.7%-68.5%
    Net Income Growth14.5%3.2%16.8%18.7%-11.7%-19.4%-18.6%-55.1%-35.1%-29.2%-115.6%-57.3%
    Margins Quarterly            
    EBITDA Margin------------
    Operating Income Margin------------
    Net Income Margin------------
    Cash & Debt            
    Total Cash9098119129137150179187181110127142
    Total Debt223334444454
    Net Debt / (Cash)-88-95-116-126-134-146-176-183-176-106-123-138
    Cash Flows Quarterly            
    FCF from Operations-15-21-15-12-17-20-17-17-14-17-12-10
    Cash Flows TTM            
    FCF from Operations TTM-63-65-64-66-71-68-66-61-53-48-43-40
    Returns to Shareholders Quarterly            
    Dividends000000000000
    Share Repurchases-0-0-0-0-0-0-0-0-0-0-0-0
    Return on Invested Capital (ROIC) Quarterly            
    ROIC-24.0%-27.1%-29.6%-30.5%-36.7%-37.5%-50.4%-53.6%-44.8%-52.2%-73.4%-66.1%
    Return on Invested Capital (ROIC) TTM            
    ROIC TTM-25.2%-28.0%-31.0%-34.4%-38.3%-40.4%-45.1%-45.5%-39.9%-52.0%-58.5%-57.3%

    Segment Financials

    Net Income by Segment
    $ Mil202520242023
    Research and development of precision oncology therapies-78-81-60
    Total-78-81-60


    Assets by Segment
    $ Mil202320222021
    Research and development of precision oncology therapies138181107
    Total138181107


    Price Behavior

    Price Behavior
    Market Price$1.72 
    Market Cap ($ Bil)0.1 
    First Trading Date11/15/2022 
    Distance from 52W High-42.9% 
       50 Days200 Days
    DMA Price$1.98$1.80
    DMA Trendupdown
    Distance from DMA-12.9%-4.3%
     3M1YR
    Volatility70.6%89.3%
    Downside Capture174.80169.08
    Upside Capture186.42146.08
    Correlation (S&P 500)32.5%28.9%
    ACRV Betas & Captures as of 9/30/2026

     1M2M3M6M1Y3Y
    Beta2.082.132.012.101.981.72
    Up Beta4.230.282.582.772.461.77
    Down Beta11.6310.565.392.852.111.84
    Up Capture88%291%140%214%242%151%
    Bmk +ve Days6162766132424
    Stock +ve Days9202861116341
    Down Capture84%1%68%133%145%112%
    Bmk -ve Days16263760120328
    Stock -ve Days12193258123379

    [1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
    Based On 1-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with ACRV
    ACRV-2.8%89.3%0.37-
    Sector ETF (XLV)24.2%16.0%1.1618.8%
    Equity (SPY)17.1%12.7%0.9628.4%
    Gold (GLD)-0.6%29.4%-0.0211.8%
    Commodities (DBC)49.3%20.7%1.82-9.7%
    Real Estate (VNQ)5.7%13.7%0.1510.6%
    Bitcoin (BTCUSD)-27.9%43.7%-0.6321.2%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How
    Based On 5-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with ACRV
    ACRV-36.1%101.3%-0.10-
    Sector ETF (XLV)8.4%15.2%0.3517.4%
    Equity (SPY)13.6%17.1%0.6023.1%
    Gold (GLD)17.9%18.9%0.768.3%
    Commodities (DBC)10.0%19.5%0.391.5%
    Real Estate (VNQ)1.2%18.8%-0.0515.8%
    Bitcoin (BTCUSD)8.5%51.8%0.3411.5%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How
    Based On 10-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with ACRV
    ACRV-20.1%101.3%-0.10-
    Sector ETF (XLV)11.1%16.7%0.5417.4%
    Equity (SPY)15.4%17.9%0.7323.1%
    Gold (GLD)12.0%16.4%0.608.3%
    Commodities (DBC)8.2%18.1%0.371.5%
    Real Estate (VNQ)4.8%20.7%0.1915.8%
    Bitcoin (BTCUSD)63.5%66.2%1.0311.5%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How

    Short Interest

    Short Interest: As Of Date9302026
    Short Interest: Shares Quantity1.6 Mil
    Short Interest: % Change Since 915202634.4%
    Average Daily Volume0.4 Mil
    Days-to-Cover Short Interest4.4 days
    Basic Shares Quantity41.8 Mil
    Short % of Basic Shares3.9%

    Earnings Returns History

    Updated 9/15/2026
    Expand for More
     Forward Returns
    Earnings Date1D Returns5D Returns21D Returns
    8/12/20267.6%39.0%16.3%
    5/13/20260.0%-8.3%-22.9%
    3/19/20263.7%-7.3%8.5%
    1/8/2026-34.6%-38.0%-43.4%
    11/13/20258.2%9.2%16.9%
    8/13/20256.1%-0.8%16.0%
    5/14/2025-3.5%0.9%5.3%
    3/25/2025-51.6%-68.8%-63.1%
    ...
    SUMMARY STATS   
    # Positive977
    # Negative799
    Median Positive6.8%9.2%16.3%
    Median Negative-5.5%-8.3%-16.3%
    Max Positive10.6%39.0%30.9%
    Max Negative-51.6%-68.8%-63.1%
     Collapse to Preview
     Forward Returns
    Earnings Date1D Returns5D Returns21D Returns
    8/12/20267.6%39.0%16.3%
    5/13/20260.0%-8.3%-22.9%
    3/19/20263.7%-7.3%8.5%
    1/8/2026-34.6%-38.0%-43.4%
    11/13/20258.2%9.2%16.9%
    8/13/20256.1%-0.8%16.0%
    5/14/2025-3.5%0.9%5.3%
    3/25/2025-51.6%-68.8%-63.1%
    11/13/2024-5.5%-24.0%-16.3%
    8/13/2024-4.5%9.7%25.2%
    5/14/2024-1.4%0.8%-11.0%
    3/28/202410.6%3.5%30.9%
    11/9/2023-19.2%-8.6%-11.4%
    8/11/20236.8%-4.8%-0.1%
    5/9/20236.8%10.9%-1.9%
    3/13/20235.1%-0.2%-50.4%
    SUMMARY STATS   
    # Positive977
    # Negative799
    Median Positive6.8%9.2%16.3%
    Median Negative-5.5%-8.3%-16.3%
    Max Positive10.6%39.0%30.9%
    Max Negative-51.6%-68.8%-63.1%

    SEC Filings

    Expand for More
    Report DateFiling DateFiling
    06/30/202608/12/202610-Q
    03/31/202605/13/202610-Q
    12/31/202503/19/202610-K
    09/30/202511/13/202510-Q
    06/30/202508/13/202510-Q
    03/31/202505/14/202510-Q
    12/31/202403/27/202510-K
    09/30/202411/13/202410-Q
    06/30/202408/13/202410-Q
    03/31/202405/14/202410-Q
    12/31/202303/28/202410-K
    09/30/202311/09/202310-Q
    06/30/202308/11/202310-Q
    03/31/202305/09/202310-Q
    12/31/202203/28/202310-K
    09/30/202212/15/202210-Q
     Collapse to Preview
    Report DateFiling DateFiling
    06/30/202608/12/202610-Q
    03/31/202605/13/202610-Q
    12/31/202503/19/202610-K
    09/30/202511/13/202510-Q
    06/30/202508/13/202510-Q
    03/31/202505/14/202510-Q
    12/31/202403/27/202510-K
    09/30/202411/13/202410-Q
    06/30/202408/13/202410-Q
    03/31/202405/14/202410-Q
    12/31/202303/28/202410-K
    09/30/202311/09/202310-Q
    06/30/202308/11/202310-Q
    03/31/202305/09/202310-Q
    12/31/202203/28/202310-K
    09/30/202212/15/202210-Q
    06/30/202211/16/2022424B4

    Recent Forward Guidance

    Updated 10/4/2026

    Latest: Q2 2026 Earnings Reported 8/12/2026

    Forward GuidanceGuidance Change
    MetricSourceLowMidHigh% Chg% DeltaChangePrior
    2027 Cash RunwayReported 4 33.3% RaisedGuidance: 3 for 2027


    Prior: Q1 2026 Earnings Reported 5/13/2026

    Forward GuidanceGuidance Change
    MetricSourceLowMidHigh% Chg% DeltaChangePrior
    Q3 2027 Cash RunwayReported 3   RaisedGuidance: 2 for Q2 2027

    Insider Activity

    Updated 10/7/2026
    Expand for More
    #OwnerTitleHoldingActionFiling DatePriceSharesTransacted
    Value    		Value of
    Held Shares    		Form
    1Miller, MaryChief Legal OfficerDirectSell100720261.99294585162,613Form
    2Blume-Jensen, PeterPresident and CEODirectSell82720262.2114,03630,9694,920,387Form
    3Peterson, KatharineChief Accounting OfficerDirectSell82020262.0110120336,246Form
    4Miller, MaryChief Legal OfficerDirectSell82020262.01185372164,838Form
    5Gamelin, ErickChief Development OfficerDirectSell82020262.01400804105,710Form
     Collapse to Preview
    #OwnerTitleHoldingActionFiling DatePriceSharesTransacted
    Value    		Value of
    Held Shares    		Form
    1Miller, MaryChief Legal OfficerDirectSell100720261.99294585162,613Form
    2Blume-Jensen, PeterPresident and CEODirectSell82720262.2114,03630,9694,920,387Form
    3Peterson, KatharineChief Accounting OfficerDirectSell82020262.0110120336,246Form
    4Miller, MaryChief Legal OfficerDirectSell82020262.01185372164,838Form
    5Gamelin, ErickChief Development OfficerDirectSell82020262.01400804105,710Form
    6Devroe, EricChief Operating OfficerDirectSell82020262.016041,214294,161Form
    7Blume-Jensen, PeterPresident and CEODirectSell82020262.011,2292,4704,510,617Form
    8Blume-Jensen, PeterPresident and CEOSee FootnoteSell82020262.01484973775,577Form
    9Levy, Adam DChief Financial OfficerDirectSell80620261.571,1421,793103,633Form
    10Miller, MaryChief Legal OfficerDirectSell72320261.765731,008144,661Form
    11Blume-Jensen, PeterPresident and CEODirectBuy11620261.6849,00082,1243,512,512Form
    12Levy, Adam DChief Financial OfficerDirectBuy11620261.708,83214,99935,635Form
    13Devroe, EricChief Operating OfficerDirectBuy11520261.7210,00017,218129,665Form

    Industry Resources

    External Quote Links


    Prefer one of these to Trefis? Tell us why.
    Core Cache Last Updated: 10/14/2026